Latest Medtech News
Australian medical robotics company Vexev has raised $6 million to accelerate FDA 510(k) clearance and U.S. commercialization of VxWave, its robotic tomographic ultrasound platform designed to make vascular imaging more standardized and accessible.
VxWave combines robotics, AI, and ultrasound to automate vascular imaging acquisition, initially targeting dialysis vascular access monitoring. In a multi-site clinical study with U.S. Renal Care, the system achieved a 94% scanning success rate when operated by non-specialist clinical staff, demonstrating its potential to improve consistency and access to imaging.
The funding will support regulatory activities, manufacturing scale-up, and commercialization as Vexev expands its platform into broader vascular disease applications.
“We believe high-quality vascular imaging should be available wherever patients receive care, not only when a specialist is available,” said John Carroll, PhD, co-founder and CEO of Vexev. “Our vision is to build an autonomous imaging platform that helps clinicians make faster, more consistent and more informed decisions across vascular disease.”
